Dextroamphetamine
| Dextroamphetamine | |
|---|---|
| Salts [] | |
|---|---|
| Dextroamphetamine phosphate | |
| Dextroamphetamine hemisaccharate | |
| Dextroamphetamine hemisulfate | |
| Dextroamphetamine adipate | |
| Dextroamphetamine hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 135.21 g/mol [1] |
| Appearance | Colorless liquid [1] |
| Density | 0.949 g/cu cm at 15 °C [1] |
| Melting point | -98 [1] |
| Boiling point | 64.7 [1] |
| Decomposition | When heated to decomposition it emits toxic nitroxides. [1] |
| Solubility | Moderately Soluble [1] |
| Predicted LogP | 1.8 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C9H13N |
| IUPAC name | (2S)-1-phenylpropan-2-amine |
| SMILES | C[C@@H](CC1=CC=CC=C1)N |
| InChI | InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1 |
| InChIKey | KWTSXDURSIMDCE-QMMMGPOBSA-N |
| CAS number | 51-64-9 |
| UNII | TZ47U051FI |
| PubChem CID | 5826 |
| Pharmacokinetics[] | |
|---|---|
| Onset | Immediate release dosing: 30–45 minutes[3] |
| Elimination half-life | 9–11 hours, pH-dependent: 7–34 hours[4] |
| Duration of action | Immediate release dosing: 3–6 hours, Extended release dosing: 8–12 hours[5][6] |
| Metabolism | CYP2D6, DBH, FMO3[7] |
| Excretion | Kidney (45%); urinary pH-dependent[8] |
| Routes of administration | By mouth, transdermal, intravenous, insufflation, rectal |
| Dependence liability | Physical: None, Psychological: Moderate |
| Addiction liability | Moderate |
| Toxicity [] | |
|---|---|
| LD50 | Mouse: - oral: 40 mg/kg Rat: - oral: 96.8 mg/kg - oral: 38 mg/kg - sc: 200 mg/kg - oral: 96.8 mg/kg [1] |
| Dosing[] |
|---|
| Insufflated [] | |
|---|---|
| Light | ≤ 7.1 mg(2x - 50.0%) |
| Common | 7.1 - 10 mg |
| Strong | 10 - 15 mg(2x - 50.0%) |
| Heavy | 15 mg |
| Extreme | 15 mg + |
| Sublingual [] | |
|---|---|
| Light | ≤ 3.3 mg(20x - 41.7%) |
| Common | 3.3 - 5 mg(26x - 54.2%) |
| Strong | 5 mg |
| Heavy | 5 mg |
| Extreme | 5 mg +(2x - 4.2%) |
| Oral [] | |
|---|---|
| Light | ≤ 5 mg(156x - 49.7%) |
| Common | 5 - 10 mg(136x - 43.3%) |
| Strong | 10 mg |
| Heavy | 10 mg |
| Extreme | 10 mg +(22x - 7.0%) |
| Intrarectal [] | |
|---|---|
| Light | ≤ 30.9 mg(2x - 66.7%) |
| Common | 30.9 mg |
| Strong | 30 - 40 mg |
| Heavy | 40 - 46 mg |
| Extreme | 46 mg +(1x - 33.3%) |
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki) We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Dextroamphetamine (also known as D-Amphetamine, Dexamphetamine, Dexamfetamine, (S)-Amphetamine, Dexadrine, (+)-Amphetamine, (+)-(S)-Amphetamine, Dexidrine, (S)-(+)-Amphetamine or (S)-1-Phenyl-2-aminopropane) is a stimulant substance of the amphetamine class.
Chemistry
Salts []
Stereochemistry []
Dextroamphetamine is a single defined stereoisomer (optical activity ( + )).
Druglikeness
Lipinski's rule of five
Dextroamphetamine matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- psychostimulants, agents used for adhd and nootropics (N06B)
- centrally acting sympathomimetics (N06BA)
- dexamfetamine (N06BA02)
MeSH Classification
Mechanism of action []
The exact mechanism of amphetamines as a class is not known. Dextroamphetamine acts by preventing reuptake, increasing release, and stimulating reverse-transport of dopamine in synaptic clefts in the striatum. Newer evidence shows amphetamines may also alter the number of dopamine transporters in synaptic clefts. [1]
Prodrugs of dextroamphetamine: Benzphetamine, Clobenzorex, Lisdexamphetamine, N-(L-Lysinamidyl)-3,4-methylenedioxyamphetamine.
Interactions []
Subjective effects []
| 0xea / Dextroamphetamine [] | |
|---|---|
Routes:
| |
| bonzi / Dextroamphetamine [] | |
|---|---|
Routes:
| |
Legal status []
- Australia: Dextroamphetamine is a Schedule 8.[9][10]
- Brazil: Dextroamphetamine is a A3.[11]
- Canada: Dextroamphetamine is Prescription only / Schedule G (CDSA I).[12]
- Germany: Dextroamphetamine is a Anlage III under the "Betäubungsmittelgesetz (BtMG)".
- United Kingdom: Dextroamphetamine is a Class B under the "Misuse of Drugs Act 1971".
- United States: Dextroamphetamine is a Schedule II under the "Controlled Substances Act".[13][14]
- European Union: Dextroamphetamine is Prescription only.[15]
- United Nations: Dextroamphetamine is a Schedule II psychotropic under the "Convention on Psychotropic Substances 1971".
- Other: Dextroamphetamine is a SE: Förteckning II.[16]
See also []
External links []
- Dextroamphetamine (Wikipedia)
- Dextroamphetamine (PubChem)
- Dextroamphetamine (Wikidata)
- Dextroamphetamine (DrugBank)
- Dextroamphetamine (ChEMBL)
- Dextroamphetamine (ChEBI)
- Dextroamphetamine (Common Chemistry)
- Dextroamphetamine (HMDB)
- Dextroamphetamine (KEGG)
- Dextroamphetamine (EPA DSSTox)
- Dextroamphetamine (Effect Index)
- Dextroamphetamine (UNII)
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5826, Dextroamphetamine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5826
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Dextroamphetamine. UNII: TZ47U051FI. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/TZ47U051FI
Green-Hernandez C, Singleton JK, Aronzon DZ. Primary Care Pediatrics. Lippincott Williams & Wilkins. 1 January 2001. https://books.google.com/books?id=o43u_qWT4asC
Adderall- dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet. DailyMed. 27 February 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81
Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. October 2012; 9(4):739–752. PMID 23065655. https://doi.org/10.1007/s13311-012-0150-9
Stahl SM. Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. March 2017.
Lemke TL, Williams DA, Roche VF, Zito W. Foye's Principles of Medicinal Chemistry. Wolters Kluwer Health/Lippincott Williams & Wilkins. 2013.
dextrostat (dextroamphetamine sulfate) tablet [Shire US Inc.]. DailyMed. August 2006. https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=1645
Therapeutic Goods (Poisons Standard—February 2023) Instrument 2022. Australian Government Federal Register of Legislation. 26 September 2022. https://www.legislation.gov.au/Series/F2022L01257
Fuller K. ADHD Stimulant Prescribing Regulations & Authorities in Australia & New Zealand. AADPA. 20 February 2022. https://aadpa.com.au/adhd-stimulant-prescribing-regulations-in-australia-new-zealand/
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Product monograph brand safety updates. Health Canada. 6 June 2024. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database/label-safety-assessment-update/product-monograph-brand-safety-updates.html
Dexedrine spansule- dextroamphetamine sulfate capsule, extended release. DailyMed. 10 January 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc717b9b-22ea-4c60-a1d4-ee38a40bce78
Xelstrym- dextroamphetamine patch, extended release. DailyMed. 6 January 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0862f02a-72a8-41cc-8845-57cf4974bb6f
List of nationally authorised medicinal products : Active substance(s): dexamfetamine : Procedure No. PSUSA/00000986/202109. Ema.europa.eu. https://www.ema.europa.eu/documents/psusa/dexamfetamine-list-nationally-authorised-medicinal-products-psusa/00000986/202109_en.pdf
Attentin, Tablett 5 mg. FASS. 24 April 2026. https://fass.se/health/product/20110721000068/fass-text
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | ok | 2026-11-20 04:08:29 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 04:08:25 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 04:08:25 |
| gsrs | ok | 2026-11-20 04:08:29 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015516) | 2026-11-20 04:08:25 |
| kegg | ok | 2026-11-20 04:08:26 |
| pubchem | ok | 2026-11-20 04:08:25 |
| missing (no r/tripreports posts mention it) | 2026-11-20 04:08:25 | |
| sider | missing (not in SIDER) | 2026-11-20 04:08:25 |
| structure | ok | 2026-11-20 04:08:25 |
| wikipedia | ok | 2026-11-20 04:08:25 |